Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
120 hedge funds and large institutions have $428M invested in Cymabay Therapeutics in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 29 increasing their positions, 42 reducing their positions, and 23 closing their positions.
283% more call options, than puts
Call options by funds: $3.64M | Put options by funds: $951K
105% more capital invested
Capital invested by funds: $209M → $428M (+$219M)
26% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 23
5% more funds holding
Funds holding: 114 → 120 (+6)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
31% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$27M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$10.7M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$9.53M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$9.25M |
| 5 |
Millennium Management
New York
|
+$4.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$9.09M |
| 2 |
ECM
Engine Capital Management
New York
|
-$6.16M |
| 3 |
SCM
Sio Capital Management
New York
|
-$6.1M |
| 4 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$5.65M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.61M |
CBAY Hedge Fund Activity: Q3 2020 in Review
120 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2020, worth a combined $428M — up 105% from $209M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new CBAY positions and 23 closed out — a net gain of 6 holders — while 29 added to existing stakes and 42 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $27M. The largest seller was D.E. Shaw & Co, cutting an estimated $9.09M.
- 120 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2020, up from 114 in Q2 2020.
- Funds reported $428M of Cymabay Therapeutics stock for Q3 2020, up 105% quarter-over-quarter.
- 29 funds opened new Cymabay Therapeutics positions in Q3 2020 and 23 closed out, a net change of +6 holders.
- The largest Cymabay Therapeutics buyer in Q3 2020 was Avoro Capital Advisors, an estimated $27M added.
- The largest Cymabay Therapeutics seller in Q3 2020 was D.E. Shaw & Co, an estimated $9.09M sold.
Based on aggregated 13F filings for Q3 2020.